Movatterモバイル変換

Rinucumab

From Wikipedia, the free encyclopedia

Monoclonal antibody

Pharmaceutical compound

Rinucumab
Monoclonal antibody
Type	?
Source	Human
Target	platelet-derived growth factor receptor beta
Clinical data
Other names	REGN2176
ATC code	none
Identifiers
CAS Number	1569263-06-4
ChemSpider	none
UNII	10E3O6YI4W
Chemical and physical data
Formula	C₆₄₇₂H₉₉₇₄N₁₇₁₀O₂₀₂₂S₃₈
Molar mass	145309.21 g·mol⁻¹

Rinucumab (REGN2176) is a monoclonal antibody designed for the treatment of neovascularage-related macular degeneration.^[1]^[2]

This drug was developed by Regeneron Pharmaceuticals, Inc.

^"Rinucumab"(PDF).Statement On A Nonproprietary Name Adopted By The USAN Council.American Medical Association.
^Hussain RM, Ciulla TA (September 2017). "Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration".Expert Opinion on Emerging Drugs.22 (3):235–246.doi:10.1080/14728214.2017.1362390.PMID 28756707.S2CID 3505145.

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Human	Burosumab Denosumab
Humanized	Blosozumab^† Romosozumab

Human	Stamulumab^†

Human	Abelacimab Alirocumab Ascrinvacumab^§ Bentracimab^† Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Marstacimab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab^‡ Imciromab^‡
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Concizumab Demcizumab Emicizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Human	Anti-amyloid drugs Aducanumab^‡ Donanemab Gantenerumab^† Lecanemab Erenumab Fasinumab^† Fulranumab Opicinumab
Humanized	Bapineuzumab^† Crenezumab^† Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Semorinemab Solanezumab Tanezumab^†

Humanized	Ranibizumab

Human	Bimagrumab Trevogrumab
Humanized	Domagrozumab Landogrozumab

Hidden categories: